Bristol Myers Squibb has extended its long-term research collaboration with global CRDMO Syngene until 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data, and information technology services, to enable seamless progression from research to commercialisation. “At Bristol Myers Squibb, everything we […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!